Pfizer Inc.

34.51+0.7700+2.28%Vol 42.50M1Y Perf -21.74%
Jul 2nd, 2020 16:03 DELAYED
BID34.47 ASK34.51
Open34.62 Previous Close33.74
Pre-Market35.09 After-Market34.51
 1.35 4.00%  - -%
Target Price
40.78 
Analyst Rating
Moderate Buy 2.00
Potential %
18.17 
Finscreener Ranking
★★★+     51.94
Insiders Trans % 3/6/12 mo.
-100/-87/-89 
Value Ranking
★★★★     59.17
Insiders Value % 3/6/12 mo.
-100/-99/-98 
Growth Ranking
★★★+     55.50
Insiders Shares Cnt. % 3/6/12 mo.
-100/-99/-98 
Income Ranking
★★★+     51.90
Market Cap191.70B 
Earnings Rating
Sell
Price Range Ratio 52W %
39.75 
Earnings Date
28th Jul 2020

Today's Price Range

34.0434.84

52W Range

27.8844.56

5 Year PE Ratio Range

9.4033.70

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
7.71%
1 Month
-4.56%
3 Months
2.59%
6 Months
-11.35%
1 Year
-21.74%
3 Years
2.04%
5 Years
5.07%
10 Years
198.44%

TickerPriceChg.Chg.%
PFE34.510.77002.28
AAPL368.514.40001.21
GOOG1 464.7026.66001.85
MSFT206.261.56000.76
XOM44.080.37000.85
WFC25.340.25001.00
JNJ140.970.59000.42
FB233.42-4.1300-1.74
GE6.820.08001.19
JPM92.66-0.6000-0.64
Financial StrengthValueIndustryS&P 500US Markets
0.70
1.00
0.36
0.80
11.80
Leverage Ratio 2.60
ProfitabilityValueIndustryS&P 500US Markets
79.90
37.20
48.40
22.80
31.23
RevenueValueIndustryS&P 500US Markets
50.66B
9.12
-0.62
1.21
DividendsValueIndustryS&P 500US Markets
4.66
1.52
5.35
6.19
Payout ratio50.00
Earnings HistoryEstimateReportedSurprise %
Q01 20200.710.8012.68
Q04 20190.570.55-3.51
Q03 20190.630.7519.05
Q02 20190.770.803.90
Q01 20190.770.8510.39
Q04 20180.630.641.59
Q03 20180.760.782.63
Q02 20180.750.818.00
Earnings Per EndEstimateRevision %Trend
6/2020 QR0.64-7.25Negative
9/2020 QR0.731.39Positive
12/2020 FY2.882.86Positive
12/2021 FY2.68-1.47Negative
Next Report Date28th Jul 2020
Estimated EPS Next Report0.64
Estimates Count3
EPS Growth Next 5 Years %4.40
Volume Overview
Volume42.50M
Shares Outstanding5.55B
Trades Count192.03K
Dollar Volume1.56B
Avg. Volume30.41M
Avg. Weekly Volume38.68M
Avg. Monthly Volume35.00M
Avg. Quarterly Volume28.28M

Pfizer Inc. (NYSE: PFE) stock closed at 34.51 per share at the end of the most recent trading day (a 2.28% change compared to the prior day closing price) with a volume of 42.93M shares and market capitalization of 191.70B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 92400 people. Pfizer Inc. CEO is Albert Bourla.

The one-year performance of Pfizer Inc. stock is -21.74%, while year-to-date (YTD) performance is -11.92%. PFE stock has a five-year performance of 5.07%. Its 52-week range is between 27.88 and 44.56, which gives PFE stock a 52-week price range ratio of 39.75%

Pfizer Inc. currently has a PE ratio of 11.40, a price-to-book (PB) ratio of 2.74, a price-to-sale (PS) ratio of 3.58, a price to cashflow ratio of 12.90, a PEG ratio of 2.32, a ROA of 9.81%, a ROC of 15.44% and a ROE of 25.51%. The company’s profit margin is 31.23%, its EBITDA margin is 48.40%, and its revenue ttm is $50.66 Billion , which makes it $9.12 revenue per share.

Of the last four earnings reports from Pfizer Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.64 for the next earnings report. Pfizer Inc.’s next earnings report date is 28th Jul 2020.

The consensus rating of Wall Street analysts for Pfizer Inc. is Moderate Buy (2), with a target price of $40.78, which is +18.17% compared to the current price. The earnings rating for Pfizer Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Pfizer Inc. has a dividend yield of 4.66% with a dividend per share of $1.52 and a payout ratio of 50.00%.

Pfizer Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 29.59, ATR14 : 0.91, CCI20 : 41.88, Chaikin Money Flow : -0.16, MACD : -0.77, Money Flow Index : 61.09, ROC : 2.83, RSI : 52.26, STOCH (14,3) : 89.78, STOCH RSI : 1.00, UO : 59.48, Williams %R : -10.22), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Pfizer Inc. in the last 12-months were: Albert Bourla (Option Excercise at a value of $1 813 810), Alexander R. Mackenzie (Option Excercise at a value of $1 038 253), Angela Hwang (Option Excercise at a value of $501 313), Dawn Rogers (Option Excercise at a value of $1 010 048), Dawn Rogers (Sold 13 000 shares of value $495 690 ), Douglas M. Lankler (Option Excercise at a value of $1 063 269), Douglas M. Lankler (Sold 65 000 shares of value $2 460 372 ), Frank A. D'Amelio (Option Excercise at a value of $9 766 544), Jennifer B. Damico (Sold 4 362 shares of value $162 441 ), John Young (Option Excercise at a value of $7 765 057), Loretta V. Cangialosi (Option Excercise at a value of $1 586 062), Michael Goettler (Option Excercise at a value of $625 459), Mikael Dolsten (Sold 95 353 shares of value $3 602 681 ), Rady A. Johnson (Option Excercise at a value of $437 811), Rady A. Johnson (Sold 13 125 shares of value $503 475 ), Sally Susman (Option Excercise at a value of $5 008 366), Scott Gottlieb (Buy at a value of $141 157)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (44.44 %)
3 (37.50 %)
4 (44.44 %)
Moderate Buy
1 (11.11 %)
1 (12.50 %)
1 (11.11 %)
Hold
4 (44.44 %)
4 (50.00 %)
4 (44.44 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.13
Moderate Buy
2.00

Pfizer Inc.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor, representing over a fifth of total company sales.

CEO: Albert Bourla

Teplephone: +1 212 733-2323

Address: 235 East 42nd Street, New York 10017, NY, USA

Number of employees: 92 400

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

53%47%

Bearish Bullish

48%52%

Bearish Bullish

52%48%

News

Stocktwits